U.S., Oct. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07209241) titled 'Different Approaches for CART-EGFR-IL13Ra2 Dosing in Recurrent GBM' on Sept. 30.
Brief Summary: This is an open-label, phase 1b study to evaluate different approaches for CART-EGFR-IL13Ra2 dosing and further characterize the safety, feasibility, preliminary efficacy, and pharmacokinetics of CART-EGFR-IL13Ra2 cells in patients with EGFR-amplified glioblastoma that has recurred following prior radiotherapy.
Study Start Date: Nov. 01
Study Type: INTERVENTIONAL
Condition:
Recurrent Glioblastoma
Intervention:
BIOLOGICAL: CART-EGFR-IL13Ra2 T cells
CART-EGFR-IL13Ra2 cells are autologous T cells co-expressing two CARs targeting the cr...